RAP2C-AS1: A Promising Drug Target and Biomarker for ALS-related Neurodegeneration

Target Name: RAP2C-AS1

NCBI ID: G101928578

RAP2C-AS1

Other Name(s): RAP2C antisense RNA 1

RAP2C-AS1: A Promising Drug Target and Biomarker for ALS-related Neurodegeneration

Amyloidosis, one of the most common forms of protein-related neurodegeneration, has a poor treatment outcomes and a high mortality rate. The majority of amyloid-positive individuals will eventually develop Alzheimer's disease, a debilitating and progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques and neurofibrillary tangles in the brain. The identification of potential therapeutic targets and biomarkers has the potential to significantly improve the treatment of amyloidosis and other forms of neurodegeneration. One such target is RAP2C-AS1, a non-coding RNA molecule that has been shown to play a critical role in the development and progression of amyloidosis.

The RAP2C-AS1 gene

RAP2C-AS1 is a non-coding RNA molecule that was identified by bioinformatic analysis of RNA sequencing data from the human brain. It is located on chromosome 6 and has a length of 218 nucleotides. RAP2C-AS1 is predominantly expressed in the brain and is highly co-expressed with the protein As100, which is a known carrier protein for the neurotransmitter GABA.

The RAP2C-AS1 protein

RAP2C-AS1 is a 21.1 kDa protein that is expressed in various tissues and cells. It is highly co-expressed with As100 and is predominantly localized to the endoplasmic reticulum (ER) and the cytoplasm. RAP2C-AS1 has been shown to play a role in the regulation of gene expression and has been implicated in the development and progression of various neurological disorders, including amyloidosis.

The RAP2C-AS1-As100 interaction

The RAP2C-AS1-As100 interaction has been shown to play a critical role in the development of amyloidosis. Studies have shown that RAP2C-AS1 can interact with As100 and that this interaction is important for the stability and localization of As100 in the ER. Additionally, the interaction between RAP2C-AS1 and As100 has been implicated in the regulation of As100 stability and localization to the ER, which may contribute to the ER-associated toxicity of As100.

The potential therapeutic implications of RAP2C-AS1

The identification of RAP2C-AS1 as a potential drug target and biomarker for amyloidosis has significant implications for the treatment of this debilitating and progressive neurodegenerative disorder. By targeting RAP2C-AS1, researchers may be able to develop small molecules or other therapeutic agents that can inhibit its activity and reduce the production of amyloid in the brain. This approach has the potential to significantly improve the treatment of amyloidosis and other forms of neurodegeneration.

In conclusion, RAP2C-AS1 is a promising drug target and biomarker for amyloidosis. Its interaction with As100 and its localization to the ER make it an attractive target for small molecules and other therapeutic agents that can inhibit its activity. Further research is needed to fully understand the role of RAP2C-AS1 in the development and progression of amyloidosis and to develop effective treatments.

Protein Name: RAP2C Antisense RNA 1

The "RAP2C-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RAP2C-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets